Anticancer therapy targeting the apoptotic pathway.

[1]  G. Evan,et al.  Nuclear colocalization of cellular and viral myc proteins with HSP70 in myc-overexpressing cells , 1991, Journal of virology.

[2]  P. Hainaut,et al.  Interaction of heat‐shock protein 70 with p53 translated in vitro: evidence for interaction with dimeric p53 and for a role in the regulation of p53 conformation. , 1992, The EMBO journal.

[3]  B. Cheson,et al.  Clinical trials referral resource. , 1990, Oncology.

[4]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.

[5]  H. Villar,et al.  Design, synthesis, and evaluation of latent alkylating agents activated by glutathione S-transferase. , 1996, Journal of medicinal chemistry.

[6]  John Calvin Reed,et al.  BCL‐2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy , 1996, Journal of cellular biochemistry.

[7]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[8]  R. James,et al.  Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. , 1997, Cancer research.

[9]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[10]  D. V. Von Hoff,et al.  Activity of TER286 against human tumor colony-forming units. , 1997, Anti-cancer drugs.

[11]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[12]  John Calvin Reed,et al.  BAG‐1 modulates the chaperone activity of Hsp70/Hsc70 , 1997, The EMBO journal.

[13]  John Calvin Reed,et al.  The c‐IAP‐1 and c‐IAP‐2 proteins are direct inhibitors of specific caspases , 1997, The EMBO journal.

[14]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[15]  Fengzhi Li,et al.  Control of apoptosis and mitotic spindle checkpoint by survivin , 1998, Nature.

[16]  S. Lippman,et al.  Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Cory,et al.  The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.

[18]  P. Marks,et al.  A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J C Reed,et al.  IAPs block apoptotic events induced by caspase‐8 and cytochrome c by direct inhibition of distinct caspases , 1998, The EMBO journal.

[20]  J C Reed,et al.  Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases , 1999, The EMBO journal.

[21]  G. Clayman,et al.  Local delivery for gene therapy , 1999, Current oncology reports.

[22]  Andreeff,et al.  Apoptosis regulating proteins as targets of therapy for haematological malignancies. , 1999, Expert opinion on investigational drugs.

[23]  R. K Srivastava,et al.  Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  C. Rauch,et al.  Tumoricidal activity of tumor necrosis factor–related apoptosis–inducing ligand in vivo , 1999, Nature Medicine.

[25]  M MacFarlane,et al.  Distinct Caspase Cascades Are Initiated in Receptor-mediated and Chemical-induced Apoptosis* , 1999, The Journal of Biological Chemistry.

[26]  E. Sausville,et al.  Proteasome inhibitors: a novel class of potent and effective antitumor agents. , 1999, Cancer research.

[27]  S. Korsmeyer,et al.  BCL-2 family members and the mitochondria in apoptosis. , 1999, Genes & development.

[28]  B. Cheson,et al.  Clinical trials referral resource. Current clinical trials for the proteasome inhibitor PS-341. , 2000, Oncology.

[29]  Yi Li Yang,et al.  The IAP family: endogenous caspase inhibitors with multiple biological activities , 2000, Cell Research.

[30]  M. Hengartner.  The biochemistry of apoptosis , 2000, Nature.

[31]  R. Morimoto,et al.  The Chaperone Function of hsp70 Is Required for Protection against Stress-Induced Apoptosis , 2000, Molecular and Cellular Biology.

[32]  S. Korsmeyer,et al.  Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c , 2000, Cell Death and Differentiation.

[33]  D. Cunningham,et al.  Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  T. Cotter,et al.  Heat shock proteins – modulators of apoptosis in tumour cells , 2000, Leukemia.

[35]  Dick D. Mosser,et al.  Heat-shock protein 70 inhibits apoptosis by preventing recruitment of procaspase-9 to the Apaf-1 apoptosome , 2000, Nature Cell Biology.

[36]  H. Inagawa,et al.  A new method of antitumor therapy with a high dose of TNF perfusion for unresectable liver tumors. , 2000, Anticancer research.

[37]  K. Tew,et al.  Cellular response to a glutathione S-transferase P1-1 activated prodrug. , 2000, Molecular pharmacology.

[38]  Emad S. Alnemri,et al.  Negative regulation of the Apaf-1 apoptosome by Hsp70 , 2000, Nature Cell Biology.

[39]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.

[40]  P. Binz,et al.  Heat shock proteins in human cancer , 2000, Electrophoresis.

[41]  S. Strom,et al.  Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand , 2000, Nature Medicine.

[42]  H. Kalthoff,et al.  CD95 and TRAIL receptor-mediated activation of protein kinase C and NF-κB contributes to apoptosis resistance in ductal pancreatic adenocarcinoma cells , 2001, Oncogene.

[43]  I. Brukner.  INGN-201. Introgen Therapeutics. , 2001, Current opinion in investigational drugs.

[44]  Josef M. Penninger,et al.  Heat-shock protein 70 antagonizes apoptosis-inducing factor , 2001, Nature Cell Biology.

[45]  P. Elliott,et al.  The proteasome: a new target for novel drug therapies. , 2001, American journal of clinical pathology.

[46]  M. Gleave,et al.  Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl‐2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model , 2001, International journal of cancer.

[47]  T. Owa,et al.  Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. , 2001, Current medicinal chemistry.

[48]  P. Richardson,et al.  TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. , 2001, Blood.

[49]  J. Adams,et al.  Proteasome inhibition in cancer: development of PS-341. , 2001, Seminars in oncology.

[50]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death , 2001, Science.

[51]  N. Tanigawa,et al.  The role of survivin as a new target of diagnosis and treatment in human cancer , 2001, Medical Electron Microscopy.

[52]  Xianglin Shi,et al.  New Insights into the Role of Nuclear Factor-κB in Cell Growth Regulation , 2001 .

[53]  L. Corcos,et al.  Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. , 2001, Cancer research.

[54]  P. Workman,et al.  Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. , 2001, Cancer research.

[55]  L. Neckers,et al.  Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. , 2001, Journal of chromatography. B, Biomedical sciences and applications.

[56]  P. Marks,et al.  Histone deacetylases and cancer: causes and therapies , 2001, Nature Reviews Cancer.

[57]  R. K Srivastava.  TRAIL/Apo-2L: mechanisms and clinical applications in cancer. , 2001, Neoplasia.

[58]  S. Park,et al.  Alternative splicing variants of c-FLIP transduce the differential signal through the Raf or TRAF2 in TNF-induced cell proliferation. , 2001, Biochemical and biophysical research communications.

[59]  J. Blank,et al.  The ups and downs of MEK kinase interactions. , 2001, Cellular signalling.

[60]  A. Tolcher.  Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer. , 2001, Seminars in oncology.

[61]  C. Rudin,et al.  ONYX-015. Onyx Pharmaceuticals. , 2001, Current opinion in investigational drugs.

[62]  T. Libermann,et al.  Molecular sequelae of proteasome inhibition in human multiple myeloma cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[63]  C. Rudin,et al.  A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  John Calvin Reed,et al.  Apoptosis-based therapies , 2002, Nature Reviews Drug Discovery.

[65]  Michael Fraser,et al.  Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. , 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[66]  J. Hiscott,et al.  On the TRAIL to apoptosis. , 2002, Cytokine & growth factor reviews.

[67]  G. l'Allemain.  [Update on . . . the proteasome inhibitor PS341]. , 2002, Bulletin du cancer.

[68]  G. L’Allemain.  Actualités sur... l'inhibiteur du protéasome PS341 , 2002 .

[69]  B. Barlogie,et al.  High-dose therapy and immunomodulatory drugs in multiple myeloma. , 2002, Seminars in oncology.

[70]  K. Totpal,et al.  Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors , 2002, Oncogene.

[71]  B. Sela,et al.  [Survivin: anti-apoptosis protein and a prognostic marker for tumor progression and recurrence]. , 2002, Harefuah.

[72]  J. Licht,et al.  Histone deacetylases as therapeutic targets in hematologic malignancies. , 2002, Current opinion in hematology.

[73]  Karen L. Siedlecki,et al.  Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  S. Lipton,et al.  Dueling Activities of AIF in Cell Death versus Survival DNA Binding and Redox Activity , 2002, Cell.

[75]  J. Adams.  Proteasome inhibition: a novel approach to cancer therapy. , 2002, Trends in molecular medicine.

[76]  K. Tanabe,et al.  Current status of the molecular mechanisms of anticancer drug-induced apoptosis , 2002, Cancer Chemotherapy and Pharmacology.

[77]  R. Moritz,et al.  HtrA2 Promotes Cell Death through Its Serine Protease Activity and Its Ability to Antagonize Inhibitor of Apoptosis Proteins* , 2002, The Journal of Biological Chemistry.

[78]  G. Tortora,et al.  Inhibition of bcl-2 as cancer therapy. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[79]  J. Adams.  Development of the proteasome inhibitor PS-341. , 2002, The oncologist.

[80]  D. Neuberg,et al.  Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. , 2002, Cancer research.

[81]  M. Jäättelä.  Programmed cell death: many ways for cells to die decently , 2002, Annals of medicine.

[82]  E. White,et al.  Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death , 2002, Oncogene.

[83]  G. Wood,et al.  Apoptosis and melanoma: molecular mechanisms , 2003, The Journal of pathology.

[84]  L. Mao,et al.  Proteomic identification of heat shock protein 70 as a candidate target for enhancing apoptosis induced by farnesyl transferase inhibitor , 2003, Proteomics.

[85]  C. Stroh,et al.  Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. , 2003, Drug discovery today.

[86]  L. Kèlland,et al.  Farnesyl transferase inhibitors in the treatment of breast cancer , 2003, Expert opinion on investigational drugs.

[87]  L. Neckers.  Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification. , 2003, Current medicinal chemistry.

[88]  N. Smith,et al.  The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer. , 2003, The Journal of urology.

[89]  R. Maestro,et al.  Role of Caspases, Bid, and p53 in the Apoptotic Response Triggered by Histone Deacetylase Inhibitors Trichostatin-A (TSA) and Suberoylanilide Hydroxamic Acid (SAHA)* , 2003, The Journal of Biological Chemistry.

[90]  X. Liu,et al.  Survivin Enhances Aurora-B Kinase Activity and Localizes Aurora-B in Human Cells* , 2003, The Journal of Biological Chemistry.

[91]  M. Peter,et al.  The CD95(APO-1/Fas) DISC and beyond , 2003, Cell Death and Differentiation.

[92]  L. Khachigian,et al.  Signaling and transcriptional control of Fas ligand gene expression , 2003, Cell Death and Differentiation.

[93]  A. Ashkenazi,et al.  Apo2L/TRAIL and its death and decoy receptors , 2003, Cell Death and Differentiation.

[94]  E. D. de Vries,et al.  Death Receptor Ligands, in Particular TRAIL, to Overcome Drug Resistance , 2004, Cancer and Metastasis Reviews.

[95]  L. Neckers,et al.  Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity , 2004, Investigational New Drugs.

[96]  M. Grever,et al.  Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent , 2004, Cancer Chemotherapy and Pharmacology.

[97]  R. Korneluk,et al.  XIAP: Apoptotic brake and promising therapeutic target , 2001, Apoptosis.

[98]  P. Elliott,et al.  Proteasome Inhibition: a New Strategy in Cancer Treatment , 2000, Investigational New Drugs.